About Circadian Therapeutics
Founded in 2016 as a spin-out from Oxford University, our world-leading science is based on the understanding of the molecular control of circadian rhythms, enabling us to develop unique therapeutics to treat serious diseases associated with disruption of the body clock.
Dr. Mike Snape
Dr. Snape is a neurobiologist who has spent 32 years in the pharmaceutical industry working for large and emerging biopharmaceutical companies. He has experience founding and funding companies at inception through IPO on the public markets. His principal experience lies in the area of demonstrating clinical proof-of-concept with novel targeted therapeutics in rare diseases. He is named an inventor in numerous patents and is a scientific advisor to several patient foundations. He earned a PhD in neurobiology from London University after study at Maudsley and Bethlem Hospital and holds a faculty position at Case Western University.
Dr. Mark Sampson
Chief Executive Officer
Most recently Chief Medical Officer of Shield Therapeutics, Dr Sampson has had a distinguished, 30-year career as a pharmaceutical physician in both Clinical Development and Medical Affairs roles across pharmaceutical, biotech and consumer products companies including Gilead, Amgen and SmithKline Beecham.
Julia Jones FCA
Chief Finance Officer
After graduating from Loughborough University in 1997, Julia joined PricewaterhouseCoopers and qualified as a Chartered Accountant in 2001. Julia then gained a broad range of experience with key finance positions in Industry. For the last thirteen years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made support to many companies, including those with venture capital backing, privately owned businesses, and charities.
Glenn is the founder of Hydrophis Gas which is developing new chemistry to capture marine CO2 and convert it into bicarbonate powder through biomimicry. He is Chairman of Hutano Diagnostics, making aptamer-based rapid tests for viral illnesses such as Covid-19. Formerly an investment banker, he has over 23 years’ experience of growing businesses through raising debt and equity, corporate (re)structuring and regulatory advisory. He has a PhD from Oxford where he was a Rhodes Scholar in the 1990s, and undergraduate law degrees from universities in Japan and Australia.
Prof Russell Foster, CBE, FRS
Director & Academic Founder
Prof Aarti Jagannath
Aarti’s pioneering findings on the molecular underpinnings of circadian rhythms have been published in prestigious peer reviewed journals including Cell and Current Biology.
Aarti currently runs her own research group at the University of Oxford as a BBSRC David Phillips Fellow and works on the molecular mechanisms by which circadian rhythms are entrained, or are set to the right time. She was awarded the L’Oreal Women in Science Fellowship in 2015.
Dr Sridhar Vasudevan
His pioneering work has been published in several prestigious peer-review journals including; Nature Chemical Biology and Nature Communications, he remains widely cited.
Sri currently heads his own laboratory at Oxford working on the identification and targeting of novel molecular pathways leading to the potential modulation of circadian rhythms and sleep.
Development and Regulatory Support & Consultancy
Labrador Technology Ltd
Project Management & IT